Lantheus: 90% Rally Now Tests Valuation, Reimbursement Risk

Lantheus (LNTH) shares have surged about 90% since early 2024. Management hit the operational targets that a Seeking Alpha analysis had highlighted. The financial results behind that gain tell a more complicated story.

Revenue rose about 11% in 2024. Net income fell 24% to $227 million. Free cash flow dropped 73% to $81 million. The divergence between top-line growth and cash generation is the central tension in the stock.

Lantheus's main product, the cardiac PET agent Pylarify, drove much of the revenue expansion. Pylarify competes against generic F-18 imaging agents and GE Healthcare's Myoview. The competitive dynamic is shifting. Medicare reimbursement for cardiac PET is under annual review. A cut in the 2025 rate would directly affect Pylarify's profitability.

At roughly 18.5x trailing EV/EBITDA, the stock prices in continued improvement. That multiple sits above the median for diagnostic imaging companies, the analysis noted. It leaves little room for a setback. The bull case rests on Pylarify maintaining its market share, new product launches contributing incremental revenue, and margins recovering from the 2024 compression.

The margin picture requires explanation. Net income fell even as revenue grew. Free cash flow fell faster. The Seeking Alpha analysis pointed to higher R&D spending and changes in working capital as contributing factors. The company is investing in pipeline agents, though near-term commercial payoff is unproven. A rebound in free cash flow is necessary to justify the current valuation.

The catalyst calendar narrows the risk window. The Centers for Medicare & Medicaid Services typically sets payment rates for cardiac PET in the second half of the year. A neutral or favorable rate decision would remove one layer of uncertainty. A cut would force investors to re-evaluate Pylarify's revenue trajectory. FDA decisions on pipeline agents offer upside optionality but no guaranteed timeline.

What would confirm the bullish setup? Revenue growth holding above 10% in 2025. Pylarify not losing share to generics. Operating margins expanding. Free cash flow recovering toward prior levels. Each of those factors would support the premium multiple.

What would weaken it? A Medicare cut. Generic pricing pressure. R&D costs rising without a commercial payoff. The stock's 90% gain has already discounted good news. The next leg depends on execution against these catalysts.

The analyst who wrote the original analysis holds no position in LNTH. That neutral stance adds weight to the caution embedded in the numbers. Lantheus reports quarterly results throughout 2025. The Medicare rate decision will come in the second half. Between now and then, the stock trades on sentiment and quarterly read-throughs. The easy money, buying at a deep discount, has been made. The current price requires near-perfect execution.